"Antipsychotic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
| Descriptor ID |
D014150
|
| MeSH Number(s) |
D27.505.696.277.950.040 D27.505.954.427.210.950.040 D27.505.954.427.700.872.331
|
| Concept/Terms |
Antipsychotic Agents- Antipsychotic Agents
- Agents, Antipsychotic
- Antipsychotics
- Major Tranquilizers
- Tranquilizers, Major
- Tranquillizing Agents, Major
- Agents, Major Tranquillizing
- Major Tranquillizing Agents
- Neuroleptic Drugs
- Drugs, Neuroleptic
- Neuroleptics
- Tranquilizing Agents, Major
- Agents, Major Tranquilizing
- Major Tranquilizing Agents
- Antipsychotic Drugs
- Drugs, Antipsychotic
- Neuroleptic Agents
- Agents, Neuroleptic
Antipsychotic Effect- Antipsychotic Effect
- Effect, Antipsychotic
- Antipsychotic Effects
- Effects, Antipsychotic
|
Below are MeSH descriptors whose meaning is more general than "Antipsychotic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antipsychotic Agents".
This graph shows the total number of publications written about "Antipsychotic Agents" by people in this website by year, and whether "Antipsychotic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 1 | 5 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 3 | 4 |
| 2001 | 6 | 2 | 8 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 5 | 1 | 6 |
| 2005 | 6 | 4 | 10 |
| 2006 | 2 | 2 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 4 | 1 | 5 |
| 2009 | 7 | 0 | 7 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 2 | 5 |
| 2012 | 2 | 4 | 6 |
| 2013 | 5 | 2 | 7 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 1 | 5 |
| 2016 | 5 | 1 | 6 |
| 2017 | 3 | 2 | 5 |
| 2018 | 1 | 0 | 1 |
| 2019 | 4 | 0 | 4 |
| 2020 | 6 | 1 | 7 |
| 2021 | 1 | 0 | 1 |
| 2022 | 4 | 0 | 4 |
| 2023 | 9 | 0 | 9 |
| 2024 | 3 | 1 | 4 |
| 2025 | 2 | 0 | 2 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antipsychotic Agents" by people in Profiles.
-
Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized? Schizophr Bull. 2026 Jan 16; 52(1).
-
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial. CNS Drugs. 2026 Jan; 40(1):99-109.
-
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2025 Aug 19; 68(1):e116.
-
Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition. Eur Neuropsychopharmacol. 2024 Oct; 87:18-23.
-
Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations. Int J Neuropsychopharmacol. 2024 02 01; 27(2).
-
Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence. Schizophr Bull. 2024 01 01; 50(1):14-21.
-
Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes. Adv Neurobiol. 2024; 40:685-723.
-
The Use of Dispensary-Obtained Tetrahydrocannabinol as a Treatment for Neuropsychiatric Symptoms of Dementia. J Clin Psychiatry. 2023 09 18; 84(6).
-
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. Schizophr Bull. 2023 07 04; 49(4):903-913.
-
A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2023 08; 73:65-74.